Sample diversity is critical to the development of quality market research insights that help improve strategies around patient care. Even with this knowledge, reaching underrepresented populations in pharmaceutical market research is an ongoing challenge. Now that we...

Adelphi Research is a global market research consultancy that inspires action and drives change. We’ve been providing insights that impact strategic decision-making for pharmaceutical and healthcare organisations for over 30 years. Our services span the development...

As we enter a new year, our end goal remains the same – to inspire action and drive change. We are always on the lookout for ways to enhance the insights we bring to our clients, whether we are using innovative technology with agility, understanding behaviour, or...

Over the last few months our team has been busy attending a range of interesting conferences to discuss all things innovation and healthcare research. We’ve attended conferences by some of the most interesting voices in the industry, including Intellus, JP Morgan...

Our team here at Adelphi are always busy keeping on top of the latest trends and developments in pharma and healthcare research, and this month has been no different, with Adelphi attending the A&I Summit in Barcelona. The Analytics & Insights Summit was held...

In the third article in our series, we start by considering respondents cannot tell us everything. To get to insightful ideas that change behaviour and help clients’ businesses we need to take some more steps. First, we need to ask better questions. We’ll start by...

Every day, we are inspired to make a difference to patient lives all across the world. From day one, it’s always been important to us to keep evolving and transforming to put forth exceptional results to continue improving the lives of patients. With that, we’ve...

In the first article in our Barriers and Biases in Pharma Research series, we looked at the role of cognitive biases and heuristics in simplifying complex choices to produce imperfect but ‘good enough’ decision–making. We might think there are times when ‘good enough’...

Why is this approach to economic analysis, which applies psychological insights from individual behaviour, sustaining its relevance?

Rheumatoid disorders ranging from Rheumatoid Arthritis (RA) and Psoriatic Arthritis (PsA) to ankylosing spondylitis (AS) have seen huge therapeutic advancements over the last decade.

Did you attend Reuters Pharma Europe 2021 which took place virtually on 11 – 22 October? Our team did and they captured some interesting takeaways on the hottest themes and key case studies.

We know there is an inconsistency between what people say and how they actually behave. To better understand the disconnect, we regularly integrate the lens of behavioral economics (BE) across our projects to illuminate latent drivers of decision-making often in complex contexts.